In a new study, a Yale-led research team uncovers how a very low calorie diet can rapidly reverse type 2 diabetes in animal models. If confirmed in people, the insight provides potential new drug targets for treating this common chronic disease, said the researchers.
Research shows that teenagers who used a mobile health app once a day in conjunction with medical care improved concussion symptoms.
In a recent study, researchers investigated whether there is a link between children’s antibiotics and the rise of autoimmune diseases such as type 1 diabetes and celiac disease.
We’re no stranger to robotics in the medical field. Robot-assisted surgery is becoming more and more common. Many training programs are starting to include robotic and virtual reality scenarios to provide hands-on training for students without putting patients at risk.
Merck KGaA’s pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs turned up at the ACR scientific conference in San Diego to roll out a promising look at some key Phase II osteoarthritis data — which comes with a critical caveat.
After reading part 1 of our series Guidance for Visiting Foreign Clients you should probably know how to prepare before visiting foreign clients. In part 2 we give you more tips on how conduct your meeting for a more successful outcome.
Merck & Co., Inc. (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS™ (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Novartis announced positive topline results from the global MONALEESA-7 trial, the second Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. The MONALEESA-7 trial met its primary endpoint of progression-free survival (PFS) in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
As NousCom CEO Alfredo Nicosia likes to say, the Basel-based biotech is a relative fledgling at 2-years of age. But the core research team there has been working together for quite a few years.
New research published in the journal BMC Cell Biology shows that old human cells can be rejuvenated using chemicals similar to resveratrol, which is a substance found in red wine and dark chocolate.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.